To study the significance of Gal-1 silencing in contributing to the anti-HCC effects of miR-22, we investigated whether delivery of AAV9-Gal-1, which was already highly expressed in HCC, would attenuate the anti-HCC effects of miR-22. This evidence concerns the gene LGALS1 and hepatocellular carcinoma.